Biomarker Core

生物标志物核心

• 批准号: 10406875
• 负责人: Julius C Hedden
• 金额: $ 62.42万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10406875
• 关键词: Acceleration; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Amyloid; Area; Autopsy; Biological; Biological Markers; Clinical; Clinical Trials; Collection; Consult; Data; Development; Disease; Early Diagnosis; Enrollment; Future; Genetic; Genetic Heterogeneity; Genomics; Goals; Health Disparities Research; Heterogeneity; Histopathology; Image; Individual; Informatics; Institution; Intervention; Investments; Link; Liquid substance; Magnetic Resonance Imaging; Measures; Nerve Degeneration; New York City; Participant; Pathologic; Pathology; Population; Positron-Emission Tomography; Process; Recommendation; Research; Research Personnel; Risk Factors; Route; Sampling; Services; Ships; Sleep disturbances; Standardization; Symptoms; Technical Expertise; Therapeutic Trials; Tracer; Training; Underrepresented Minority; United States National Institutes of Health; Validation; Work; base; blood-based biomarker; cohort; data sharing; design; disease heterogeneity; disorder risk; factor A; health disparity; imaging biomarker; imaging facilities; improved; innovation; magnetic resonance imaging biomarker; metropolitan; mild cognitive impairment; neuroimaging; neuroimaging marker; neuropathology; open data; pre-clinical; resilience; tau Proteins

Mount Sinai ADRC (Sano): Biomarker Core (Core G) – Research Summary Biomarkers provide indirect evidence of the pathological hallmarks of Alzheimer's disease (AD), affording earlier diagnosis of AD and increased likelihood that individuals enrolled in therapeutic trials targeting these pathologies will benefit from the intervention. Biomarker research is increasingly necessary for enabling bidirectional translational efforts, for understanding heterogeneity of the disease, and for identifying resilience factors. The proposed Biomarker Core will consolidate and bolster existing efforts involving biomarker research with the goals of improving early diagnosis, identifying indicators of resilience, characterization of disease heterogeneity, and acceleration of clinical trial efforts. The aims of the Biomarker Core are to: 1) Provide services for biomarker collection and analysis on the ADRC cohort and to facilitate ADRD research broadly. The Core will coordinate biomarker characterization of the ADRC cohort using the NIH-AA research framework (A/T/N). The Core will provide recommendations for acquisition with specific MRI sequences, PET tracers, and fluid biomarkers; analytic pipelines; and expertise to support project design. 2) Promote wide and rapid sharing through interactions with other Cores, across the institution, and with outside institutions. The Core will facilitate informatics for banking and sharing processed neuroimaging data and fluid samples, help to route biomarker- characterized participants to best-matched studies and trials, and support a culture of open science to encourage collaborative efforts across institutional boundaries. 3) Leverage imaging biomarker data to catalyze development of innovative projects focused on biomarkers as early indicators of disease risk and to characterize heterogeneity and resilience factors. The Core will actively work with investigators to optimize inclusion of biomarkers in projects and will provide access to biomarker-characterized participants. 4) Develop the future through biomarker training and involvement in project-based activities. The Core will provide biomarker training to REC trainees and to investigators new to ADRD research, consult with investigators to develop projects involving biomarkers, and will link clinical ADRD researchers to technical expertise in biomarkers. Across these aims, the Core will emphasize the early stages of disease (preclinical and mild cognitive impairment), with a goal of maximizing utility to existing observational projects and increasing the likelihood that characterized participants will remain in the sample for enrollment into clinical trials. The Core will prioritize characterization of under- represented minorities to contribute to health disparities research and increase the generalizability of ADRD biomarker research. These Core activities will support acquisition, analysis, informatics, and data sharing to integrate biomarker research into the efforts of the ADRC to accelerate understanding of disease hetereogeneity by illuminating biological differences associated with vulnerability or resilience factors that underlie the expression of clinical symptoms.

西奈山 ADRC (Sano)：生物标志物核心 (Core G) – 研究摘要 生物标志物提供了阿尔茨海默病 (AD) 病理特征的间接证据，可以更早地发现 AD 的诊断以及个体参加针对这些病理的治疗试验的可能性增加 将会从干预中受益。生物标志物研究对于实现双向性越来越有必要 转化工作，了解疾病的异质性，并确定恢复因素。这 拟议的生物标志物核心将巩固和加强涉及生物标志物研究的现有努力，以实现以下目标 改善早期诊断、确定恢复力指标、疾病异质性特征，以及 加快临床试验工作。生物标志物核心的目标是： 1）为生物标志物提供服务 对 ADRC 队列进行收集和分析，并广泛促进 ADRD 研究。核心将协调 使用 NIH-AA 研究框架 (A/T/N) 对 ADRC 队列进行生物标志物表征。核心将 提供特定 MRI 序列、PET 示踪剂和液体生物标志物采集的建议； 分析管道；和支持项目设计的专业知识。 2）通过以下方式促进广泛和快速的共享 与机构内其他核心以及外部机构的互动。核心将促进 用于存储和共享处理过的神经影像数据和液体样本的信息学，有助于路由生物标志物 对参与者进行最匹配的研究和试验，并支持开放科学文化，以鼓励 跨越机构界限的协作努力。 3) 利用成像生物标志物数据来催化 开发创新项目，重点关注生物标志物作为疾病风险的早期指标并表征 异质性和弹性因素。核心将积极与调查人员合作，以优化纳入 项目中的生物标志物，并将为具有生物标志物特征的参与者提供机会。 4）发展未来 通过生物标志物培训和参与基于项目的活动。核心将提供生物标志物培训 对于 REC 学员和新接触 ADRD 研究的研究人员，与研究人员协商开发项目 涉及生物标志物，并将临床 ADRD 研究人员与生物标志物的技术专业知识联系起来。跨越这些 目标，核心将强调疾病的早期阶段（临床前和轻度认知障碍），目标是 最大化现有观测项目的效用并增加参与者特征的可能性 将保留在样本中以参加临床试验。核心将优先考虑欠缺的特征 代表少数群体为健康差异研究做出贡献并提高 ADRD 的普遍性 生物标志物研究。这些核心活动将支持采集、分析、信息学和数据共享，以 将生物标志物研究纳入 ADRC 的工作中，以加速对疾病异质性的了解 通过阐明与脆弱性或复原力因素相关的生物学差异 临床症状的表达。